Veracyte (VCYT) PT, Estimates Bumped at Piper Jaffray Despite Q2 Rev Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Veracyte (VCYT) Tops Q2 EPS by 2c, Amends Agreement with Sanofi's Genzyme
August 13, 2014 4:12 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.31), $0.02 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $8.7 million versus the consensus estimate of $9.36 million.
The company also announced an agreement to amend terms of its co-promotion agreement with Genzyme... More
